We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A New Method To Evaluate Vaccine Safety
News

A New Method To Evaluate Vaccine Safety

A New Method To Evaluate Vaccine Safety
News

A New Method To Evaluate Vaccine Safety

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "A New Method To Evaluate Vaccine Safety"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vaccines are safe and potent pharmaceutical products that prevent infectious diseases caused by viruses and bacteria, and reduce the spread of pathogens among the population. A vaccine prevents an infectious disease because the body develops an ability to recognize and destroy the pathogen. Vaccines are generally designed from a weakened pathogen, or parts of it. The vaccine industry uses effective methods to ensure vaccine safety, and constantly develops new methods as well.

The pertussis vaccine, which also belongs to the Finnish national vaccination program, contains the surface structures of the pertussis bacteria and inactivated forms of the pertussis toxin produced by the bacteria. The pertussis toxin attaches to the surface of the cell, penetrates it, and destroys the vital control system of the cell.

The research group at the University of Turku has led the development of the new method that can be used to ensure the safety of the pertussis toxin in the pertussis vaccine. The new iGIST method (Interference in Gαi-mediated Signal Transduction) detects how the pertussis toxin destroys the vital control system of the cell.

– Compared to the current methods in the vaccine industry, iGIST is more effective and enables the detection of up to 100 times lower levels of pertussis toxin. iGIST is entirely based on using laboratory grown, human-based cells. Therefore, it may significantly reduce the use of animal testing in the vaccine industry, says Dr Arto Pulliainen from the University of Turku who was the principal investigator of the research group that was in charge of developing the method.

The method was developed in collaboration with researchers from the University of Turku, Åbo Akademi University, Medical University of Lublin in Poland, and Eindhoven University of Technology in the Netherlands.

Reference: Paramonov VM, Sahlgren C, Rivero-Müller A, Pulliainen AT. iGIST—A Kinetic Bioassay for Pertussis Toxin Based on Its Effect on Inhibitory GPCR Signaling. ACS Sens. 2020;5(11)3438–3448. doi:10.1021/acssensors.0c01340

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement